TipRanks
Go Ultimate55% OFF

Compare Clinuvel Pharmaceuticals (UR9) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:UR9Clinuvel Pharmaceuticals EUR 4.43EUR 227.90M10.35-29.47%Moderate BuyUnlock the DE:UR9 analyst price target with TipRanks PremiumDE:UR9Unlock the DE:UR9 top-analyst price target with TipRanks Premium
AU:ACRAcrux AUD 0.01AUD 6.12M-7.14-28.57%―Unlock the AU:ACR analyst price target with TipRanks PremiumDE:UR9 vs AU:ACRUnlock the AU:ACR top-analyst price target with TipRanks Premium
AU:SPLStarpharma Holdings LimitedAUD 0.44AUD 217.31M-26.0230.63%―Unlock the AU:SPL analyst price target with TipRanks PremiumDE:UR9 vs AU:SPLUnlock the AU:SPL top-analyst price target with TipRanks Premium
AU:PYCPYC Therapeutics LimitedAUD 1.90AUD 1.85B-30.2054.47%Strong BuyUnlock the AU:PYC analyst price target with TipRanks PremiumDE:UR9 vs AU:PYCUnlock the AU:PYC top-analyst price target with TipRanks Premium
AU:BOTBotanix Pharmaceuticals LimitedAUD 0.01AUD 27.63M-0.28-92.59%Moderate BuyUnlock the AU:BOT analyst price target with TipRanks PremiumDE:UR9 vs AU:BOTUnlock the AU:BOT top-analyst price target with TipRanks Premium
AU:BIOBiome Australia LtdAUD 0.35AUD 83.31M21.12-23.91%Moderate BuyUnlock the AU:BIO analyst price target with TipRanks PremiumDE:UR9 vs AU:BIOUnlock the AU:BIO top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:UR9Clinuvel Pharmaceuticals 4.43-1.87-29.64%
AU:ACRAcrux 0.01-0.00-33.33%
AU:SPLStarpharma Holdings Limited0.430.0927.94%
AU:PYCPYC Therapeutics Limited1.900.7159.53%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.12-92.31%
AU:BIOBiome Australia Ltd0.35-0.10-22.22%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts